132 related articles for article (PubMed ID: 9509380)
1. Plasma MHPG response to yohimbine treatment in women with hypoactive sexual desire.
Piletz JE; Segraves KB; Feng YZ; Maguire E; Dunger B; Halaris A
J Sex Marital Ther; 1998; 24(1):43-54. PubMed ID: 9509380
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women.
Safarinejad MR; Hosseini SY; Asgari MA; Dadkhah F; Taghva A
BJU Int; 2010 Sep; 106(6):832-9. PubMed ID: 20151970
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.
Braunstein GD; Sundwall DA; Katz M; Shifren JL; Buster JE; Simon JA; Bachman G; Aguirre OA; Lucas JD; Rodenberg C; Buch A; Watts NB
Arch Intern Med; 2005 Jul; 165(14):1582-9. PubMed ID: 16043675
[TBL] [Abstract][Full Text] [Related]
4. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study.
Shifren JL; Davis SR; Moreau M; Waldbaum A; Bouchard C; DeRogatis L; Derzko C; Bearnson P; Kakos N; O'Neill S; Levine S; Wekselman K; Buch A; Rodenberg C; Kroll R
Menopause; 2006; 13(5):770-9. PubMed ID: 16932240
[TBL] [Abstract][Full Text] [Related]
5. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD.
Rasmusson AM; Hauger RL; Morgan CA; Bremner JD; Charney DS; Southwick SM
Biol Psychiatry; 2000 Mar; 47(6):526-39. PubMed ID: 10715359
[TBL] [Abstract][Full Text] [Related]
6. Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder.
Caruso S; Agnello C; Intelisano G; Farina M; Di Mari L; Cianci A
Urology; 2004 May; 63(5):955-9. PubMed ID: 15134988
[TBL] [Abstract][Full Text] [Related]
7. Yohimbine in the treatment of orgasmic dysfunction.
Adeniyi AA; Brindley GS; Pryor JP; Ralph DJ
Asian J Androl; 2007 May; 9(3):403-7. PubMed ID: 17486282
[TBL] [Abstract][Full Text] [Related]
8. Noradrenergic response to acute ethanol administration in healthy subjects: comparison with intravenous yohimbine.
McDougle CJ; Krystal JH; Price LH; Heninger GR; Charney DS
Psychopharmacology (Berl); 1995 Mar; 118(2):127-35. PubMed ID: 7617798
[TBL] [Abstract][Full Text] [Related]
9. Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine.
Stine SM; Grillon CG; Morgan CA; Kosten TR; Charney DS; Krystal JH
Psychopharmacology (Berl); 2001 Mar; 154(3):274-81. PubMed ID: 11351934
[TBL] [Abstract][Full Text] [Related]
10. alpha 2-Adrenergic receptor sensitivity in depression. The plasma MHPG, behavioral, and cardiovascular responses to yohimbine.
Heninger GR; Charney DS; Price LH
Arch Gen Psychiatry; 1988 Aug; 45(8):718-26. PubMed ID: 2840050
[TBL] [Abstract][Full Text] [Related]
11. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine.
Jacobsen FM
J Clin Psychiatry; 1992 Apr; 53(4):119-22. PubMed ID: 1564046
[TBL] [Abstract][Full Text] [Related]
12. Yohimbine administration prevents over-responsiveness to epinephrine induced by simulated microgravity.
Berlan M; Verhaeghe S; Pavy-Le Traon A; Thalamas C; Lafontan M; Marques MA; Senard JM; Parent M; Galitzky J
Aviat Space Environ Med; 2002 Aug; 73(8):735-42. PubMed ID: 12182212
[TBL] [Abstract][Full Text] [Related]
13. State dependence of noradrenergic activity in a rapidly cycling bipolar patient.
Ostrow D; Halaris A; Dysken M; DeMet E; Harrow M; Davis J
J Clin Psychiatry; 1984 Jul; 45(7):306-9. PubMed ID: 6539774
[TBL] [Abstract][Full Text] [Related]
14. Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress?
Mitoma M; Yoshimura R; Sugita A; Umene W; Hori H; Nakano H; Ueda N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):679-85. PubMed ID: 18160197
[TBL] [Abstract][Full Text] [Related]
15. Effects of tryptophan depletion on responses to yohimbine in healthy human subjects.
Goddard AW; Charney DS; Germine M; Woods SW; Heninger GR; Krystal JH; Goodman WK; Price LH
Biol Psychiatry; 1995 Jul; 38(2):74-85. PubMed ID: 7578653
[TBL] [Abstract][Full Text] [Related]
16. Measurement of 3-methoxy-4-hydroxyphenylglycol (MHPG) in mouse brain by h.p.l.c. with electrochemical detection, as an index of noradrenaline utilisation and presynaptic alpha 2-adrenoceptor function.
Heal DJ; Prow MR; Buckett WR
Br J Pharmacol; 1989 Mar; 96(3):547-56. PubMed ID: 2541844
[TBL] [Abstract][Full Text] [Related]
17. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients.
Yoshimura R; Hori H; Sugita A; Ueda N; Kakihara S; Umene W; Nakano Y; Shinkai K; Mitoma M; Ohta M; Shinkai T; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1072-7. PubMed ID: 17459549
[TBL] [Abstract][Full Text] [Related]
18. Neuropharmacology of 3-isobutylmethylxanthine: effects on central noradrenergic systems in vivo.
Galloway MP; Roth RH
J Pharmacol Exp Ther; 1983 Oct; 227(1):1-8. PubMed ID: 6194283
[TBL] [Abstract][Full Text] [Related]
19. Clinical response to antidepressant treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review.
Yoshimura R; Nakamura J; Shinkai K; Ueda N
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):611-6. PubMed ID: 15276685
[TBL] [Abstract][Full Text] [Related]
20. Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer's disease.
Raskind MA; Peskind ER; Holmes C; Goldstein DS
Biol Psychiatry; 1999 Sep; 46(6):756-65. PubMed ID: 10494443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
